Chemotherapy and Radiotherapy of Gastrointestinal Tumors

1. Front Matter

   Pages I-VII

   PDF

2. The Importance of Lectin Binding Sites and Carcinoembryonic Antigen with Regard to Normal, Hyperplastic, Adenomatous, and Carcinomatous Colonic Mucosa

   • P. J. Klein, R. Osmers, M. Vierbuchen, M. Ortmann, J. Kania, G. Uhlenbruck

   Pages 1-9

3. Why Do Colon Tumours Respond Poorly to Chemotherapeutic Agents?

   • L. M. van Putten, E. A. Sluijter, T. Smink, J. H. Mulder

   Pages 10-18

4. Prospective and Controlled Studies on Multidisciplinary Treatment in Gastrointestinal Cancer

   • A. Gérard, M. Gignoux, A. Roussel, J. C. Goffin, A. Brugarolas, P. Zeitoun et al.

   Pages 19-27

5. Recent Results of Clinical Therapeutic Trials for Gastrointestinal Malignancies Conducted in the United States

   • D. L. Kisner, P. S. Schein, J. S. Macdonald

   Pages 28-40

6. Effectiveness of Postoperative Adjuvant Therapy with Cytotoxic Chemotherapy (Cytosine Arabinoside, Mitomycin C, 5-Fluorouracil) or Immunotherapy (Neuraminidase-Modified Allogeneic Cells) in the Prevention of Recurrence of Duke’s B and C Colon Cancer

   • H. Rainer, E. Kovats, H. G. Lehmann, M. Micksche, R. Rauhs, H. H. Sedlacek et al.

   Pages 41-47

7. A Controlled Prospective Trial of Adjuvant Razoxane in Resectable Colorectal Cancer

   • J. M. Gilbert, P. C. Cassell, H. Ellis, C. Wastell, K. Hellmann, M. G. Evans et al.

   Pages 48-58

8. Methyl-CCNU and Ftorafur in Treatment of Rectosigmoidal Tumors and Ftorafur Capsules in Treatment of Colorectal Tumors

   • Z. Mechl, A. Malíř

   Pages 59-64

9. High-Dose Therapy with Ftorafur in Gastrointestinal Cancer

   • H. O. Klein, P. D. Wickramanayake, R. Voigtmann, Th. Löffler, R. Mohr, H. Oerkermann

   Pages 65-81

10. Comparison of Ftorafur with 5-Fluorouracil in Combination Chemotherapy of Advanced Gastrointestinal Carcinoma

    • W. Queißer, G. Schnitzler, J. Schaefer, H. Arnold, P. Drings, D. Fritze et al.

    Pages 82-92

11. Efficacy of Dacarbazine Imidazole Carboxamide and Mitomycin C Combination Therapy in Patients with Adenocarcinoma of the Colon Refractory to 5-Fluorouracil Therapy

    • J. F. Conroy, P. I. Roda, I. Brodsky, S. B. Kahn, S. I. Bulova, E. Pequignot

    Pages 93-100

12. 5-Fluorouracil: A Comparative Pharmacokinetic Study and Preliminary Results of a Clinical Phase I Study

    • J. P. Obrecht, W. Weber, J. P. Cano, Ch. Crevoisier, P. Alberto, I. Forgo et al.

    Pages 101-107

13. Back Matter

    Pages 109-114

    PDF

Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane «±1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief period of the cell cycle in late G and/or early mitosis [12]. It does so non-selectively and most cells capable of 2 division examined so far have been affected by the drug. Even affected cells however are not destroyed immediately, but may increase in size and become multinucleate [5].

• Chemotherapy
• Radiotherapy
• Tumor
• Tumors
• therapy
• Radiaton Oncology

• Medizinische Universitätsklinik, Köln 41, Germany

  Hans Otto Klein

Policies and ethics